-

08:54:03 AM

EVFM Stock News

EVFM - Evofem Biosciences Inc

08/10/22 8:23 PM

Nasdaq : EVFM

conferenceshigh short

Evofem Biosciences to Host Investor Call on Thursday, August 11, 2022

Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows:Date:Thursday, August 1 1, 2022Time:5:00 p.m. ET (2:00 p.m. PT)Live call:(877) 4 45-9755 (U.S. toll-free) or(2 01)

RHEA-AI

neutral

08/04/22 4:01 PM

Nasdaq : EVFM

earningshigh short

Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance

Completed registrational Phase 3 trial evaluating Phexxi for the prevention of chlamydia and

RHEA-AI

neutral

08/03/22 8:24 AM

Nasdaq : EVFM

managementhigh short

Evofem Biosciences Strengthens Board of Directors

Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip, a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors. The appointment of Ms. Yip as a director expands the Board from five to

RHEA-AI

neutral

08/01/22 8:47 AM

Nasdaq : EVFM

clinical trialhigh short

Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women

Evofem Biosciences,

RHEA-AI

neutral

07/29/22 8:24 AM

Nasdaq : EVFM

high short

Evofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to Individuals

Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today commended the U.S. Department of Health and Human Services, alongside the Departments of Labor and of the Treasury ("the Tri-Agencies"), for taking action to clarify protections

RHEA-AI

neutral

07/28/22 8:47 AM

Nasdaq : EVFM

conferenceshigh short

Evofem Biosciences to Report Second Quarter 2022 Results and Provide Corporate Update on Thursday, August 4, 2022

Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows:Date:Thursday,

RHEA-AI

neutral

07/26/22 8:47 AM

Nasdaq : EVFM

high short

Evofem's House Rules Campaign Featuring Annie Murphy Receives Significant Industry Recognition

Evocative direct-to-consumer (DTC) campaign has received 12 healthcare and communications industry awards to date and has recently been shortlisted for four more awards. The national campaign features Emmy ® Award-winning spokeswoman and actress Annie Murphy and was created to generate awareness of

RHEA-AI

very positive

07/25/22 8:47 AM

Nasdaq : EVFM

high short

Evofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive Counseling

Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has developed a new educational birth control chart that provides high-level information about the different options available to women in the United States."Contraceptive counseling is one of

RHEA-AI

neutral

07/22/22 8:47 AM

Nasdaq : EVFM

high short

Evofem Biosciences Applauds U.S. House of Representatives for Passing The Right to Contraception Act

Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today applauded the 228 members of the U.S. House of Representatives who voted to pass legislation to safeguard access to contraceptives entitled The Right to Contraception Act."Today

RHEA-AI

neutral

07/21/22 8:46 AM

Nasdaq : EVFM

partnershiphigh short

Evofem Partners with a360 Media to Support Phexxi® Prescription Growth

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 10 Next

EVFM Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.evofem.com
CeoSaundra Pelletier
Security nameEvofem Biosciences Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees147
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address12400 High Bluff Dr Ste 600
StateCalifornia
CitySan Diego
Zip92130-3077
CountryUS
Phone18585501900

About Evofem Biosciences Inc

Evofem Biosciences, Inc., is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women.